NASDAQ:NEUP
Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc.'s revenue fell 92.5% in fiscal 2026 to $1.2M while operating margin fell to −1401.1%. The diluted share count rose 170.9%.Summary generated from Neuphoria Therapeutics Inc.'s SEC filings. Latest annual report filed Sep 18, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$1.2M
Revenue growth−92.5%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−1401.1%
Net margin−1145.7%
ROICn/a
Return on equity−61.7%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+170.9%
Financials
| Item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue | n/a | n/a | 16 | 1 |
| Operating income | −22 | −18 | −1 | −16 |
| Net income | −21 | −15 | −0 | −13 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- DEF 14AProxy statement
Sep 18, 2026 - 10-KAnnual report for the fiscal year ended Jun 30, 2026
Sep 18, 2026 - 8-KEntry into a material agreement
Jul 24, 2026 - 8-KOther events
May 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 10-QQuarterly report for the period ended Dec 31, 2025
Feb 17, 2026 - 4Insider transaction report
Jan 21, 2026 - 4Insider transaction report
Jan 21, 2026